On October 25, 2022 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that the Company will present new preclinical data at three upcoming scientific conferences (Press release, Lantern Pharma, OCT 25, 2022, View Source [SID1234622353]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Society of Neuro Oncology Annual Meeting in Tampa, FL on November 18, from 7:30-9:30 p.m. ET.
Poster Title: Preclinical efficacy of LP-184, a tumor site activated synthetically lethal therapeutic, in glioblastoma
Registration: View Source
San Antonio Breast Cancer Symposium in San Antonio, TX on December 8, from 8:00-9:15 a.m. ET.
Poster Title: To be announced
Registration: View Source
American Society of Hematology Annual Meeting in New Orleans, LA on December 10, from 6:30-8:30 p.m. ET.
Poster Title: To be announced
Registration: View Source
Further details on the new preclinical data as well as additional conference presentation details will be announced in the coming weeks.